Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Anti-PSA immunoreactivity in primary prostatic tissues from black African men.

Olapade-Olaopa EO, Ogunbiyi JO, Muronda CA, Okeke LI, Shittu OB, Danso AP.

Afr J Med Med Sci. 2007 Dec;36(4):311-6.

PMID:
18564646
2.

A variant epidermal growth factor receptor protein is similarly expressed in benign hyperplastic and carcinomatous prostatic tissues in black and white men.

Olapade-Olaopa EO, Moscatello DK, MacKay EH, Ogunbiyi JO, Shittu OB, Terry TR, Okeke LI, Wong AJ, Habib FK.

West Afr J Med. 2007 Jan-Mar;26(1):42-7.

PMID:
17595991
5.

Androgen receptor protein expression in prostatic tissues in Black and Caucasian men.

Olapade-Olaopa EO, Muronda CA, MacKay EH, Danso AP, Sandhu DP, Terry TR, Habib FK.

Prostate. 2004 Jun 1;59(4):460-8.

PMID:
15065095
7.

The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.

Sheridan T, Herawi M, Epstein JI, Illei PB.

Am J Surg Pathol. 2007 Sep;31(9):1351-5.

PMID:
17721190
8.

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, Epstein JI.

Urology. 2003 Jul;62(1):177-81.

PMID:
12837462
9.

Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer.

Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL.

J Urol. 2003 Sep;170(3):990-3.

PMID:
12913756
10.

Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissue.

Rubenstein M, Shaw MW, Ray V, Dubin A, McKiel CF, Guinan P.

Prostate. 1989;14(4):383-8.

PMID:
2473461
11.

Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate.

Ellis DW, Leffers S, Davies JS, Ng AB.

Am J Clin Pathol. 1984 Mar;81(3):279-84.

PMID:
6199966
12.

Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.

Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT.

Urology. 2009 Jul;74(1):177-83. doi: 10.1016/j.urology.2008.10.062. Epub 2009 May 9.

PMID:
19428074
13.

Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).

Lokant MT, Naz RK.

Andrologia. 2015 Apr;47(3):328-32. doi: 10.1111/and.12265. Epub 2014 Mar 12.

PMID:
24620795
14.
16.

Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.

Goel T, Garg S.

Urol Int. 2009;82(3):286-90. doi: 10.1159/000209359. Epub 2007 Apr 16.

PMID:
19440015
17.

Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology.

Varma M, Morgan M, Jasani B, Tamboli P, Amin MB.

Am J Clin Pathol. 2002 Aug;118(2):202-7.

PMID:
12162678
18.

The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.

Roehrborn CG.

Int J Impot Res. 2008 Dec;20 Suppl 3:S19-26. doi: 10.1038/ijir.2008.53. Review.

PMID:
19002120
19.

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia.

Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS, Slawin KM.

Prostate. 2000 Nov 1;45(3):271-6.

PMID:
11074531

Supplemental Content

Support Center